Fibromyalgia is real, exhausting and often difficult to treat. It can involve widespread pain, fatigue, sleep disruption, concentration problems, headaches and sensitivity to pain. That does not mean a fibromyalgia diagnosis automatically opens access to medical cannabis.
The careful answer is this: NICE does not recommend cannabis-based medicinal products for chronic pain in adults, and the NHS says the evidence for medical cannabis in pain is not strong enough to recommend it for pain relief. A private specialist may still assess an individual patient under UK prescribing rules, but that assessment depends on records, previous treatments, current medicines, risk factors and clinical judgement.
This article is for UK patients and carers trying to understand where fibromyalgia sits in that system. It is not medical advice and it cannot decide whether any treatment is suitable for you. Suitability, product form, dose, monitoring and whether any cannabis-based medicine is appropriate sit with a specialist prescriber.
If you are new to the wider process, start with the MCPH patient guide. If you are trying to understand pain guidance more broadly, read medical cannabis for chronic pain: what NICE says and medical cannabis and medication interactions alongside this page.
The short answer
Medical cannabis should not be presented as a standard fibromyalgia treatment. NHS fibromyalgia guidance focuses on exercise, talking therapies and medicines such as some antidepressants. NICE’s medical cannabis guideline sits across chronic pain and says not to offer several cannabis-based medicinal products for chronic pain in adults. It also says not to offer CBD for chronic pain outside a clinical trial.
That creates a tension patients often notice. Public NHS guidance is restrictive, while private specialist clinics may still assess people with long-term pain conditions. The realistic version is not “NHS says never” and not “fibromyalgia qualifies”. It is an individual specialist assessment with a high evidence and safety bar.
For access discussions, previous treatment history matters. Patients are often asked to show that at least two relevant treatments have not worked well enough, caused problems or been unsuitable. For fibromyalgia, relevant treatments might include supervised exercise, CBT or ACT, pain-focused medicines, antidepressants used for pain, sleep or mood support, or other approaches already tried under clinical care. The exact relevance depends on the person and the records.
What fibromyalgia means in this context
The NHS describes fibromyalgia as a long-term condition that causes pain all over the body. It can also involve increased sensitivity to pain, stiffness, poor sleep, fatigue, headaches, irritable bowel symptoms and “fibro-fog”.
This matters because fibromyalgia is not just ordinary muscle pain. Many patients have a long history of symptoms, investigations, medicines, pacing strategies and frustration. A good article should not dismiss that.
It also matters because fibromyalgia can overlap with mental health symptoms, sleep problems, other pain conditions and other medicines. That makes specialist assessment more careful, not less. A prescriber would need to understand the whole picture before deciding whether a cannabis-based medicinal product is even worth discussing.
What NICE and NHS guidance say
NICE NG144 is the main NICE guideline on cannabis-based medicinal products. In its chronic pain section, NICE says not to offer nabilone, dronabinol, THC, or a CBD and THC combination to manage chronic pain in adults. It also says not to offer CBD for chronic pain in adults unless this is part of a clinical trial.
The NHS medical cannabis page gives the public-facing summary: there is some evidence medical cannabis can help certain types of pain, but the evidence is not strong enough to recommend it for pain relief. It says pain prescribing may happen in clinical trial contexts.
For fibromyalgia patients, that means MCPH should keep the boundary visible:
- fibromyalgia symptoms are real and can be life-limiting;
- medical cannabis is not a routine NHS fibromyalgia treatment;
- a diagnosis does not equal qualification;
- a private specialist assessment still has to justify evidence, safety and monitoring;
- any discussion should include side effects, interactions, impairment, mental health and treatment history.
Why private assessment can sound different
Private specialist prescribing is not the same thing as NHS commissioning. NHS England says private doctors on the GMC Specialist Register are legally able to prescribe cannabis-based products for medicinal use, and CQC says CBPMs can only be prescribed by or under the direction of a specialist doctor with relevant knowledge and expertise.
That does not override NICE. It means a specialist may assess an individual patient within professional rules. The prescriber still needs to consider the condition, evidence, safer licensed options, medicines already used, risks, follow-up and whether an unlicensed medicine is justified.
For a fibromyalgia patient, the useful question is not “Does fibromyalgia qualify me?”. It is: “Does my diagnosis, treatment history, current medication list and risk profile mean I may qualify for a specialist assessment?”
The medical cannabis qualifying conditions guide can help with that first steer. The final decision remains clinical.
Records and previous treatments
If you are preparing for an assessment, start with records rather than persuasion.
The Summary Care Record from your GP surgery is usually the practical first document. If it shows the fibromyalgia diagnosis and relevant previous treatments, that may be enough for an early eligibility check. Clinics can ask for more detail if the SCR does not show enough, such as pain clinic letters, rheumatology letters, physiotherapy notes or medicine history.
Useful preparation can include:
- the diagnosis or working diagnosis you have been given;
- the main symptoms that affect your daily life, such as pain, sleep, fatigue and function;
- relevant treatments tried, when they were tried and why they were stopped or unsuitable;
- current prescription medicines, over-the-counter medicines, supplements and any non-prescribed cannabinoid use;
- mental health history, previous adverse cannabis reactions and substance-use concerns;
- driving, work safety, pregnancy or breastfeeding considerations where relevant.
For more practical records framing, read how to request your Summary Care Record and what counts as trying two treatments.
Safety issues for fibromyalgia patients
Fibromyalgia patients may already be dealing with fatigue, poor sleep, dizziness, anxiety, depression, antidepressants, gabapentinoids, opioids, sleep medicines or other treatments that affect alertness. That makes safety review central.
The NHS medical cannabis page notes that CBD and THC can affect how other medicines work. Interaction questions are a normal part of specialist prescribing and pharmacist review. Patients do not need to panic-read lists online, but they do need to give the prescriber a complete medicines and supplement list.
Medical cannabis can also cause side effects, including drowsiness, dizziness, appetite changes, mood changes and impairment. THC-containing products may affect driving, work safety and mental health. A prescriber may ask about psychosis, schizophrenia history, bipolar or mania risk, severe depression, suicidality, substance-use concerns and previous adverse cannabis reactions.
Do not stop, switch or reduce existing fibromyalgia medicines without clinical advice. If medical cannabis is discussed at all, it should be discussed as one possible specialist-assessment topic, not as a replacement plan made from an article.
What to ask a specialist
Useful questions are practical and bounded:
- How does NICE’s chronic pain guidance affect a fibromyalgia assessment?
- Which parts of my treatment history are most relevant?
- Does my Summary Care Record show enough, or do you need extra clinic letters?
- What interactions matter with my current medicines?
- What side effects or impairment risks would be most relevant for me?
- How would treatment be reviewed, and what would count as stopping if it is not helping or is causing problems?
- How should I think about driving, work safety and travel if a THC-containing medicine is ever prescribed?
Patients can ask informed questions about forms such as flower, oil or extract if the consultation reaches that point. The prescriber decides suitability, product, dose, route and monitoring.
FAQ
Does fibromyalgia qualify for medical cannabis in the UK?
Not by diagnosis alone. Fibromyalgia may be part of a specialist assessment, but the decision depends on records, previous treatments, current medicines, risk factors and clinical judgement.
Does NICE recommend medical cannabis for fibromyalgia?
NICE NG144 does not give a fibromyalgia-specific access route. Its chronic pain recommendations say not to offer several cannabis-based medicinal products for chronic pain in adults, and not to offer CBD for chronic pain outside a clinical trial.
Why do private clinics assess fibromyalgia if NICE is restrictive?
Private specialist prescribing works through individual clinical assessment and professional responsibility. That does not make access automatic and it does not remove the need to explain evidence limits and safety.
What records are usually useful?
Start with the Summary Care Record from your GP surgery. If it clearly shows the diagnosis and relevant previous treatments, it may support an initial eligibility check. Extra letters or reports are useful if requested or if the SCR does not show enough detail.
Can this article tell me which product or dose to ask for?
No. Product, form, dose, route, monitoring and suitability are prescriber decisions. This article is a practical evidence and access explainer, not a prescribing guide.
Sources
- NHS. Medical cannabis. https://www.nhs.uk/medicines/medical-cannabis/
- NHS. Fibromyalgia overview. https://www.nhs.uk/conditions/fibromyalgia/
- NHS. Fibromyalgia treatment. https://www.nhs.uk/conditions/fibromyalgia/treatment/
- NICE. Cannabis-based medicinal products: recommendations, NG144. https://www.nice.org.uk/guidance/ng144/chapter/recommendations
- NHS England. Cannabis-based products for medicinal use. https://www.england.nhs.uk/long-read/cannabis-based-products-for-medicinal-use-cbpms/
- CQC. Cannabis-based medicinal products: what CQC expects from providers. https://www.cqc.org.uk/guidance-providers/healthcare/cannabis-based-medicinal-products-what-cqc-expects-providers
- GMC. Information for doctors on cannabis-based products for medicinal use. https://www.gmc-uk.org/professional-standards/learning-materials/information-for-doctors-on-cannabis-based-products-for-medicinal-use
Cover image brief: cover-brief.md.
